# Beta-Glucan and Rituximab in Treating Young Patients With Relapsed or Progressive Lymphoma or Leukemia, or Lymphoproliferative Disorder Related to Donor Stem Cell Transplantation

> **NCT00087009** · PHASE1 · TERMINATED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 3 (actual)

## Conditions studied

- Leukemia
- Lymphoma
- Lymphoproliferative Disorder

## Interventions

- **BIOLOGICAL:** beta-glucan
- **BIOLOGICAL:** rituximab

## Key facts

- **NCT ID:** NCT00087009
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2004-05
- **Primary completion:** 2008-08
- **Final completion:** 2008-08
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Lack of Accrual
- **Last updated:** 2013-03-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00087009

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00087009, "Beta-Glucan and Rituximab in Treating Young Patients With Relapsed or Progressive Lymphoma or Leukemia, or Lymphoproliferative Disorder Related to Donor Stem Cell Transplantation". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00087009. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*